Life
Briefing: STAT+: Six drugmakers, six months: Charting the FDA’s course in the post-Prasad era
Strategic angle: Will the FDA’s regulatory policies, particularly for rare-disease drugs, shift in the wake of Vinay Prasad’s imminent departure?
editorial-staff
1 min read
Updated 23 days ago
The FDA's regulatory policies may experience significant changes following the departure of Vinay Prasad, a key figure in the agency's recent decision-making processes.
Drugmakers are closely monitoring how these potential shifts could affect the approval pathways for rare-disease medications, which have been a focal point of Prasad's tenure.
As the agency navigates this transition, the implications for drug development timelines and market access for rare-disease therapies could be substantial.